Latest Administration News

MetalsTech Limited has raised A$3.3 million through strategic placements to fund the advancement of its Sturec Gold Mine Pre-Feasibility Study, which shows strong economic potential with a US$768 million NPV. The company is progressing metallurgical testing and ore sorting technology to enhance project value.

Axiom Properties Limited reported a $1.67 million increase in cash reserves this quarter, driven by strong performance from its PaySure business and completion of the Mt Barker Glenlea Estate project.

Tyranna Resources has completed initial steps to acquire a majority interest in Angola’s Maongo Copper-Gold Project, complementing ongoing lithium exploration at Namibe. The company is poised to restart mining activities dormant since the 1960s, backed by a solid cash position and strategic regional assets.

BWP Property Group and BWP Trust have launched a new Distribution Reinvestment Plan allowing stapled securityholders to reinvest cash distributions into additional securities, potentially at a discount and without transaction costs.

Chimeric Therapeutics has advanced its CHM CDH17 CAR-T program with dose escalation and FDA Fast Track status, alongside promising early results in AML trials and a successful $6.6 million capital raise.

Epsilon Healthcare has completed a $6.7 million sale and leaseback of its Southport manufacturing site, significantly reducing debt and securing long-term operational stability.

Prescient Therapeutics has raised $6.8 million through a Share Purchase Plan to fund the Phase 2 development of its novel cancer therapy PTX-100, while launching a discounted placement to sophisticated investors.

Clime Investment Management has reported a solid operating profit for the June quarter, declared a fully franked dividend, and announced strategic expansions in staff and product offerings.

Imagion Biosystems has made significant progress towards filing an Investigational New Drug application for its MagSense® HER2 breast cancer imaging agent, receiving encouraging feedback from the FDA and preparing for a Phase 2 clinical trial.

Paradigm Biopharmaceuticals has advanced its global Phase 3 trial for knee osteoarthritis pain with active patient recruitment in Australia and the US, backed by a $41.2 million convertible note facility. The company also expanded its osteoarthritis portfolio through the acquisition of Proteobioactives and the Pentacoxib™ oral therapy.

Bannerman Energy reported a robust $80 million cash inflow from financing in Q2 2025, offsetting significant exploration expenditures and maintaining a strong cash position.

Avecho Biotechnology reports strong progress in its Phase III clinical trial for a CBD-based insomnia treatment, with recruitment accelerating across multiple Australian sites and interim results expected early next year.